Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 15;6(1):6.
doi: 10.1186/s41824-022-00128-3.

Clinical experience with 18F-JK-PSMA-7 when using a digital PET/CT

Irina Vierasu  1 , Nicola Trotta  2 , Simone Albisinni  3 , Céline Mathey  2 , Gil Leurquin-Sterk  2 , Simon Lacroix  2 , Gaetan Van Simaeys  2 , Thierry Quackels  3 , Thierry Roumeguère  3 , Serge Goldman  2
Affiliations

Clinical experience with 18F-JK-PSMA-7 when using a digital PET/CT

Irina Vierasu et al. Eur J Hybrid Imaging. .

Abstract

Background: Digital PET/CT systems make use of a new technology with higher sensitivity and other better technological features than the analog ones. They require adaptation of the trade-off between performance, tracer dose and acquisition time. The aim of the study was to explore the performance of 18F-JK-PSMA-7 imaging when performed on a digital PET/CT with an adapted protocol, in a population of patients with prostate cancer patients (PCa). Influence of previous therapy on PET/CT performance is generally disregarded in PSMA-based imaging, despite potential influence of hormono-chemotherapy on the target expression. This potential influence was also tested in this work.

Methods: A total of 54 PCa patients experiencing biochemical recurrence were included in the study, in which we analysed the diagnostic performance of digital 18F-JK-PSMA-7 PET/CT. Compared to our protocol applied for acquisition on an analog system, administered dose and acquisition time were reduced by 20% and 50% respectively. We specifically took into consideration the influence of previous treatments on recurrence detection.

Results: We detected overall 18F-JK-PSMA-7-positive lesions in 38/54 patients (70.3%). There was no statistically significant difference regarding the detection rate between the groups of patients who had hormono-chemotherapy any time after initial diagnosis and those who never got any hormonal or chemotherapeutic treatment. Regarding the SUV max values, there was not significant difference between the two groups of patients neither in pelvic ganglions nor in other metastatic sites or the prostate region.

Conclusion: 18F-JK-PSMA7 PET/CT with administered dose and acquisition time adapted to the digital technology provides valuable information in PCa patients with biochemical recurrence.

Keywords: 18F-JK-PSMA-7 PET/CT; Biochemical recurrence; Detection rate; Prostate cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have not competing interests.

Figures

Fig. 1
Fig. 1
descriptive plots of t-tests analyses at group level
See this image and copyright information in PMC

References

    1. Afshar-Oromieh A, Debus N, Uhrig M, Hope TA, Evans MJ, Holland-Letz T, Giesel FL, Kopka K, Hadaschik B, Kratochwil C, Haberkorn U. Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45(12):2045–2054. doi: 10.1007/s00259-018-4079-z. - DOI - PMC - PubMed
    1. Ceci F, et al. (68) Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? Eur J Nucl Med Mol Imaging. 2015;42(8):1284–1294. doi: 10.1007/s00259-015-3078-6. - DOI - PubMed
    1. Ceci F, Oprea-Lager DE, Emmett L, et al. E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET. Eur J Nucl Med Mol Imaging. 2021;48:1626–1638. doi: 10.1007/s00259-021-05245-y. - DOI - PMC - PubMed
    1. Dietlein F, Hohberg M, Kobe C, Zlatopolskiy BD, Krapf P, Endepols H, Täger P, Hammes J, Heidenreich A, Neumaier B, Drzezga A, Dietlein M. An (18)F-labeled PSMA ligand for PET/CT of prostate cancer: first-in-humans observational study and clinical experience with (18)F-JK-PSMA-7 during the first year of application. J Nucl Med. 2020;61(2):202–209. doi: 10.2967/jnumed.119.229542. - DOI - PubMed
    1. Dietlein M, Kobe C, Kuhnert G, Stockter S, Fischer T, Schomäcker K, Schmidt M, Dietlein F, Zlatopolskiy BD, Krapf P, Richarz R, Neubauer S, Drzezga A, Neumaier B. Comparison of [(18)F]DCFPyL and [(68)Ga]Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer. Mol Imaging Biol. 2015;17(4):575–584. doi: 10.1007/s11307-015-0866-0. - DOI - PMC - PubMed

LinkOut - more resources